Palvella Therapeutics, Inc.
QTORIN™ rapamycin
microcystic lymphatic malformations
Resolved
133days ago
Phase 3 readout · Feb 24, 2026
What's at stake
Phase 3 trial results for QTORIN™ rapamycin in microcystic lymphatic malformations are due Feb 24, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Blinded independent review demonstrated pre-treatment stability during the 8-week run-in period, followed by marked improvement on QTORIN™ rapamycin, supporting SELVA’s single-arm, baseline-controlled design”